Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) announced that its management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026, at 11:00 a.m. EST. A live audio webcast of the presentation will be accessible via the investor information section of Myriad’s website at investor.myriad.com.

Market Context

The prior -46.74% MYGN reaction to Q2 2026 earnings gives this conference scheduling notice historic...

Analysis

The prior -46.74% MYGN reaction to Q2 2026 earnings gives this conference scheduling notice historical context rather than a result update. The active S-3 shelf and recent net selling were additional risks to monitor.

Key Figures

Conference edition: 21st Annual Presentation date: September 10, 2026 Presentation time: 11:00am EST

3 metrics

Conference edition 21st Annual Wells Fargo Healthcare Conference

Presentation date September 10, 2026 Wells Fargo Healthcare Conference

Presentation time 11:00am EST September 10, 2026

Historical Context

5 past events · Latest: Jul 30 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 30	2Q26 earnings	Negative	-46.7%	Revenue declined 11%, gross margin fell, and 2026 guidance was revised.
Jul 23	earnings scheduling	Neutral	+0.7%	Company scheduled second-quarter results and a conference call for July 30.
Jul 21	prenatal test launch	Positive	-0.2%	FirstGene launched with four screens from one maternal blood draw.
Jul 02	prostate cancer meta-analysis	Positive	-0.2%	Prolaris data covered 8,478 patients across 14 studies and showed prognostic significance.
Jun 23	MRD availability expansion	Positive	+2.9%	Precise MRD expanded across three cancers, with MONITOR-Breast findings in 154 patients.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

MYGN’s recent positive product and clinical announcements generally produced limited or negative price reactions, while the latest earnings release aligned with a sharp decline.

Key Terms

molecular diagnostic testing, precision medicine

2 terms

molecular diagnostic testing medical

"a leader in molecular diagnostic testing and precision medicine"

Molecular diagnostic testing uses tools that read the genetic material or specific molecules from a tissue, blood, or swab sample to detect disease, identify pathogens, or predict how a patient will respond to treatment. Think of it like a highly detailed fingerprint check for the biology of an illness. Investors care because these tests drive sales, regulatory scrutiny, and reimbursement decisions, so accuracy, adoption, and approval directly affect a company’s revenue and growth prospects.

precision medicine medical

"a leader in molecular diagnostic testing and precision medicine"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21^st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST.

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at investor.myriad.com.

About Myriad Genetics 
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Andria Rosell
(385) 202-3510 
PR@myriad.com

FAQ

When will Myriad Genetics (MYGN) present at the 2026 Wells Fargo Healthcare Conference?

Myriad Genetics will present on Thursday, September 10, 2026, at 11:00 a.m. EST. According to Myriad Genetics, the event takes place during the 21st Annual Wells Fargo Healthcare Conference in Boston.

How can investors access the Myriad Genetics (MYGN) presentation at the 2026 Wells Fargo Healthcare Conference?

Investors can access the presentation via a live audio webcast on Myriad Genetics’ website. According to Myriad Genetics, the webcast link will be available in the investor information section at investor.myriad.com.

Where is the 2026 Wells Fargo Healthcare Conference presentation by Myriad Genetics (MYGN) being held?

Myriad Genetics’ presentation will be held in Boston as part of the 21st Annual Wells Fargo Healthcare Conference. According to Myriad Genetics, the session is scheduled for September 10, 2026, at 11:00 a.m. EST.

Is the Myriad Genetics (MYGN) Wells Fargo Healthcare Conference presentation available online for replay?

The announcement confirms a live audio webcast but does not specify replay availability. According to Myriad Genetics, investors should access the webcast link in the investor information section of investor.myriad.com at the scheduled time.

What type of event is Myriad Genetics (MYGN) participating in on September 10, 2026?

Myriad Genetics management will present at the 21st Annual Wells Fargo Healthcare Conference. According to Myriad Genetics, this is a healthcare-focused investor conference, with the company presenting at 11:00 a.m. EST in Boston.